Immunotherapy combinations for advanced kidney cancer

31 Oct 2018

Kidney cancer news

23 Mar 2023

Savolitinib and durvalumab for metastatic papillary kidney cancer

23 Mar 2023

One Cancer Voice petition: 80,000 demand diagnosis and treatment is top priority

20 Mar 2023

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

20 Mar 2023

Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer

16 Mar 2023

Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer

16 Mar 2023

Improved health-related quality of life using a mindfulness app for kidney cancer patients

16 Mar 2023

How time of day of immunotherapy infusion affects kidney cancer outcomes

15 Mar 2023

Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

9 Mar 2023

TKI treatment breaks may not affect outcomes in kidney cancer

7 Mar 2023

ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer

7 Mar 2023

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

6 Mar 2023

ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.

Registered charity in England, Wales (1164238), and Scotland (SC051330).

Helpline: 0800 121 8721

support@actionkidneycancer.org

Immunotherapy combinations for advanced kidney cancer

Immunotherapy combinations for advanced kidney cancer

Kidney cancer news

Savolitinib and durvalumab for metastatic papillary kidney cancer

One Cancer Voice petition: 80,000 demand diagnosis and treatment is top priority

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer

Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer

Improved health-related quality of life using a mindfulness app for kidney cancer patients

How time of day of immunotherapy infusion affects kidney cancer outcomes

Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

TKI treatment breaks may not affect outcomes in kidney cancer

ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

Most used tags

Archives

Address

Helpline

About Action Kidney Cancer

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Policies

Follow

Immunotherapy combinations for advanced kidney cancer

Immunotherapy combinations for advanced kidney cancer

Share this Page:

Share this Page:

Kidney cancer news

Savolitinib and durvalumab for metastatic papillary kidney cancer

One Cancer Voice petition: 80,000 demand diagnosis and treatment is top priority

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer

Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer

Improved health-related quality of life using a mindfulness app for kidney cancer patients

How time of day of immunotherapy infusion affects kidney cancer outcomes

Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

TKI treatment breaks may not affect outcomes in kidney cancer

ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer

ASCO GU 2023: A triple combination for previously untreated kidney cancer patients

ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab

Most used tags

Archives

Address

Helpline

About Action Kidney Cancer

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Policies

Follow